Involving A Nucleic Acid Encoding An Enzyme Patents (Class 435/6.18)
-
Publication number: 20120035077Abstract: This invention provides modified nucleotide sequences encoding luciferase that have greater expression than wild type luciferase.Type: ApplicationFiled: May 27, 2011Publication date: February 9, 2012Applicant: SwitchGear GenomicsInventors: Nathan D. Trinklein, Shelley Force Aldred
-
Patent number: 8110354Abstract: The in vivo and in vitro use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. The eukaryotic cells include a variety of cell types, e.g. insect, reptile, fish, mammal and tumor cells. The suitable materials for transport include biochemicals such as reporter molecules, antibiotics, biopharmaceuticals and carbohydrates including polysaccharides, lipopolysaccharides, polynucleotides, such as DNA and RNA, and glycoproteins and proteins including antigens, enzymes, antibodies, receptors and hormones. In addition, Invaplex enhances the immune response to DNA vaccines and also can function by itself as a vaccine against shigellosis.Type: GrantFiled: September 21, 2009Date of Patent: February 7, 2012Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Edwin V. Oaks, Robert W. Kaminski
-
Publication number: 20120028264Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.Type: ApplicationFiled: July 25, 2011Publication date: February 2, 2012Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
-
Publication number: 20120020954Abstract: Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.Type: ApplicationFiled: March 28, 2010Publication date: January 26, 2012Inventors: Anat Achiron, Michael Gurevich
-
Publication number: 20120014876Abstract: The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled 1 and/or frizzled 2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.Type: ApplicationFiled: February 18, 2010Publication date: January 19, 2012Applicants: ACADEMISCH ZIEKENHUIS MAASTRICHT, UNIVERSITEIT MAASTRICHTInventors: Wessel Matthijs Blankesteijn, Hilde Laeremans, Tilman Mathias Hackeng
-
Publication number: 20120009581Abstract: A method is provided in various embodiments for determining a profile data set for predicting the survivability of a subject with prostate cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification under measurement conditions that are substantially repeatable for measuring the amount of RNA corresponding to at least 1 constituent from Table 1. Alternatively, the method uses electrophoresis or immunohistochemistry for measuring the mount of protein corresponding to at least 1 constituent from Table 20. The profile data set comprises the measure of each constituent.Type: ApplicationFiled: July 8, 2009Publication date: January 12, 2012Inventors: Danute M. Bankaitis-Davis, Lisa Siconolfi, Kathleen Storm, Karl Wassmann
-
Patent number: 8092784Abstract: Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease.Type: GrantFiled: November 21, 2006Date of Patent: January 10, 2012Assignee: Biotium, Inc.Inventors: Fei Mao, Hui Cen, Wai-yee Leung
-
Publication number: 20120003662Abstract: Methods and kits for determining if one or more animals have mastitis and for monitoring animals and the quality of the milk they produce are disclosed. Kits and test assays disclosed are used to determine the quantity of proteasomes and proteins thereof, the activity of proteasome enzymes, the quantity of proteasome bound and regulating proteins, and the quantity of ubiquinated protein. Components and reagents for use in the kits and assays are also disclosed.Type: ApplicationFiled: July 26, 2011Publication date: January 5, 2012Applicant: University of Medicine and Dentistry of New JerseyInventor: Kiran Madura
-
Publication number: 20120005779Abstract: An isolated nucleic acid fragment encoding a plastidic phosphoglucomutase protein is disclosed. Also disclosed is the construction of a chimeric gene encoding all or a substantial portion of the plastidic phosphoglucomutase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the plastidic phosphoglucomutase in a transformed host cell.Type: ApplicationFiled: March 25, 2011Publication date: January 5, 2012Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventors: Stephen M. Allen, Karlene H. Butler, Thomas J. Carlson, William D. Hitz, Johan M. Stoop
-
Publication number: 20120004125Abstract: This invention relates to an isolated nucleic acid fragment encoding a diacylglycerol acyltransferase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the diacylglycerol acyltransferase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the diacylglycerol acyltransferase in a transformed host cell.Type: ApplicationFiled: December 22, 2010Publication date: January 5, 2012Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: Rebecca E. Cahoon, Edgar Benjamin Cahoon, Karlene H. Butler, Anthony J. Kinney
-
Publication number: 20110321197Abstract: A method for producing a plant with increased yield as compared to a corresponding wild type plant whereby the method comprises at least the following step: increasing or generating in a plant or a part thereof one or more activities selected from the group consisting of 17.6 kDa class I heat shock protein, 26.Type: ApplicationFiled: October 2, 2009Publication date: December 29, 2011Applicant: BASF Plant Science GmbHInventors: Hardy Schön, Oliver Thimm, Gerhard Ritte, Oliver Bläsing, Koen Bruynseels, Yves Hatzfeld, Valerie Frankard, Ana Isabel Sanz Molinero, Christophe Reuzeau, Steven Vandenabeele
-
Patent number: 8084209Abstract: The present invention provides methods for assessing a subject's responsiveness to a HMGCR inhibitor therapy, and selection of a HMGCR inhibitor therapy based upon such methods. The invention further provides methods for identifying agents that modulate HMGCR activity, e.g., through modulating HMGCR mRNA splicing, while avoiding elevation of the statin-resistant isoform of HMGCR.Type: GrantFiled: July 21, 2006Date of Patent: December 27, 2011Assignee: Children's Hospital & Research Center OaklandInventors: Marisa Lin Wong Medina, Ronald M. Krauss
-
Patent number: 8084210Abstract: The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.Type: GrantFiled: November 19, 2010Date of Patent: December 27, 2011Assignee: Theranostics LaboratoryInventors: Patrick A. Gladding, Arzu Gunes, Marja-Liisa Dahl, Mark W. Webster
-
Publication number: 20110307965Abstract: This invention provides the identification of a 16 base pair deletion in a splice site region between exons 10 and 11 of the dog PDK4 gene that is linked to dilated cardiomyopathy (DCM). Also provided are methods for detecting DCM and methods of breeding dogs to reduce the prevalence of DCM.Type: ApplicationFiled: June 7, 2011Publication date: December 15, 2011Inventor: Kathryn M. Meurs
-
Publication number: 20110306517Abstract: This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells are provided.Type: ApplicationFiled: August 19, 2011Publication date: December 15, 2011Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Andrew L. Feldman, Ahmet Dogan, George Vasmatzis, Mark Law, David I. Smith
-
Patent number: 8076075Abstract: An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen for or diagnose subjects at high risk for developing a psychiatric, neuropsychiatric, or neurological disorders. The assay of the GCH1 genotype, with or without biopterin or a BH4 or BH4 system assay, may also be used to determine antipsychotic or mood stabilizer medication, as well as other treatments. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.Type: GrantFiled: October 17, 2007Date of Patent: December 13, 2011Assignee: The Research Foundation for Mental Hygiene, Inc.Inventors: James D. Clelland, Catherine L. Clelland
-
Patent number: 8071307Abstract: The present invention provides a method of discriminating a relative risk for the morbidity of atopic dermatitis of a test subject comprising: analyzing gene polymorphism of two or more of genes related to onset of atopic dermatitis using a sample isolated from a statistically significant number of normal persons and patients of atopic dermatitis to determine relative ratios (percentages (%)) related to the individual gene polymorphism of individual derived from the analysis; and calculating an odds ratio according to specified gene polymorphism from the relative ratio; and using, as a discrimination criterion, a combination of two or more of gene polymorphisms showing a synergetically higher odds ratio than odds ratios according to individual gene polymorphism.Type: GrantFiled: April 3, 2006Date of Patent: December 6, 2011Assignee: Asubio Pharma Co., Ltd.Inventors: Keiko Tanaka, Julian M. Hopkin
-
Publication number: 20110294697Abstract: Disclosed is a system for detecting a protease inside a cell. In one embodiment, the system includes a chimeric protein that comprises as covalently linked components: 1) at least one optionally masked signal protein; 2) at least one protease-specific cleavage site; and 3) at least one detectable amino acid sequence. The invention has a wide spectrum of applications including use in the detection of novel protease inhibitors inside cells and tissue.Type: ApplicationFiled: December 7, 2010Publication date: December 1, 2011Inventors: Inhwan Hwang, Dae Heon Kim, Yong Jik Lee
-
Publication number: 20110293631Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e g inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.Type: ApplicationFiled: May 27, 2011Publication date: December 1, 2011Applicant: NORTHWESTERN UNIVERSITYInventors: Praveen Thumbikat, Anthony J. Schaeffer, Joseph Done, David J. Klumpp, Charles Rudick
-
Publication number: 20110293585Abstract: Compositions and methods for treating lysosomal storage diseases are disclosed. Lysosomal dysfunction is usually the result of deficiency of a single enzyme necessary for the metabolism of lipids, glycoproteins (sugar containing proteins) or mucopolysaccharides which are fated for breakdown or recycling. The compositions contain triplex-forming molecules which can be used to induce site-specific homologous recombination in mammalian cells when combined with donor DNA molecules, by stimulating cellular DNA synthesis, recombination, and repair mechanisms. The methods are particular useful for correcting point mutations in genes associated with lysosomal storage diseases such as Gaucher's disease, Fabry disease, and Hurler syndrome. Methods for determining the frequency of target gene repair and assessing the restoration of the enzymatic activity of corrected polypeptides are also disclosed. Ex vivo and in vivo methods of gene correction in patients are also provided.Type: ApplicationFiled: April 21, 2011Publication date: December 1, 2011Inventors: Jacob del Campo, Ranjit S. Bindra, Peter M. Glazer
-
Publication number: 20110289607Abstract: The present invention relates to a method for inhibiting expression of a target gene, which comprises introducing a cell, tissue, or individual organism with a double-stranded polynucleotide comprising DNA and RNA having a substantially identical nucleotide sequence with at least a partial nucleotide sequence of the target gene.Type: ApplicationFiled: July 5, 2011Publication date: November 24, 2011Applicants: Kaoru SAIGO, ALPHAGEN CO., LTD.Inventors: Kumiko TEI, Takahide Kaji, Ryu Ueda, Kaoru Saigo
-
Publication number: 20110287963Abstract: One aspect of the present invention relates to a reporter system for detection of protein-protein interactions in the periplasm of a prokaryotic host cell. The reporter system includes a first expression system which has a nucleic acid molecule encoding a first fragment of a reporter protein molecule, a nucleic acid molecule encoding a first signal sequence, and a nucleic acid molecule encoding a first member of a putative binding pair, where the nucleic acid molecule encoding the first fragment, the nucleic acid molecule encoding the first signal sequence, and the nucleic acid molecule encoding the first member of the putative binding pair are operatively coupled to permit their expression in a prokaryotic host cell as a first fusion protein.Type: ApplicationFiled: November 16, 2009Publication date: November 24, 2011Applicant: CORNELL UNIVERSITYInventors: Matthew P. Delisa, Thomas Mansell
-
Publication number: 20110287957Abstract: The invention pertains to a method for early detection and screening of colorectal cancer in human subjects based on RNA isolated from blood obtained from said subject. According to the invention, the expression of at least 3, 5, 8, 30, 60, 102, 202, 55, 1002 or 1002 RNAs listed in Tables 1-15 are measured. Using the invention, an accurate and noninvasive screening and diagnosis tool for colorectal cancer is provided with a sensitivity of at least 80% and a specificity of 85% that has high clinical utility and the potential for broad adoption.Type: ApplicationFiled: May 19, 2011Publication date: November 24, 2011Applicant: Signature Diagnostics AGInventors: Andre Rosenthal, Bernd Hinzmann, Tobias Mayr, Hans-Peter Adams
-
Publication number: 20110287438Abstract: The present invention discloses a sensor chip for screening a topoisomerase inhibitor and a screening method thereof. The sensor chip comprises topoisomerase I and a biochip. The topoisomerase I is immobilized on the biochip, and the topoisomerase I has DNA catalytic activity. This provides a rapid screening method for topoisomerase I inhibitors.Type: ApplicationFiled: September 21, 2010Publication date: November 24, 2011Applicant: TAIPEI MEDICAL UNIVERSITYInventors: Chun-Mao Lin, Hsiang-Ping Tsai, Chwen-Ming Shih, Jau-Lang Hwang, Chi Ming Lee
-
Publication number: 20110287440Abstract: The invention provides a means for reconstituting I?B kinase in yeast in order to study the structure and regulation of IKK and to produce pharmacological therapies to block IKK. This invention can be used to express an IKK complex that is biochemically identical to IKK isolated from native cells and in coupled in vitro kinase assays to screen for its upstream regulators. The IKK expressed by reconstituting the yeast can be used to screen for unknown substrates and for pharmacological therapies that block its activity. The invention could also be used to screen for compounds that enhance its activity. The IKK may also be used as a source of material for crystallization and X-ray diffraction analysis.Type: ApplicationFiled: August 1, 2011Publication date: November 24, 2011Inventors: Ebrahim Zandi, Beth Schomer Miller
-
Publication number: 20110281750Abstract: Disclosed herein are methods and kits for identifying clinically isolated syndrome (CIS) patients at high risk of developing multiple sclerosis (MS).Type: ApplicationFiled: July 24, 2009Publication date: November 17, 2011Applicant: The Regents of the University of California, a California CorporationInventors: Jean-Christophe Corvol, Daniel Pelletier, Stephen L. Hauser, Jorge R. Oksenberg, Sergio Baranzini
-
Publication number: 20110281270Abstract: The invention is in the field of molecular diagnostics for cancer, in particular, for acute myeloid leukemia (AML). The invention provides methods for diagnosing AML patients with a favorable prognosis. We have found that not all AML patients carrying a CEBPA mutation may have a more favorable prognosis. We found that only the group with double mutations, i.e., biallelic mutations, have a particularly favorable prognosis. We also found a method that distinguishes mono-allelic CEBPA mutations from bi-allelic mutations.Type: ApplicationFiled: November 13, 2009Publication date: November 17, 2011Applicant: Erasmus University Medical Center RotterdamInventors: Erik Van Beers, Bas Wouters, Hendrik Rudolf Delwel, Peter Jacobus Maria Valk, Bob Löwenberg
-
Publication number: 20110281264Abstract: The present invention relates to an in vitro method for diagnosing and/or predicting hereditary cerebellar ataxia in a dog, and/or identifying a dog which is healthy carrier of hereditary cerebellar ataxia, comprising determining the presence or absence of an homozygous or heterozygous genetic variation in the arylsulfatase G gene sequence in a biological sample from said dog, as compared with the arylsulfatase G gene sequence of a healthy non-carrier dog, wherein the presence of said homozygous genetic variation indicates that said dog is or will be affected by hereditary cerebellar ataxia, and the presence of said heterozygous genetic variation indicates that said dog is healthy carrier of hereditary cerebellar ataxia, said dog being of a breed selected in the group consisting of American Staffordshire Terrier, American Pit Bull Terrier and Pit Bull type.Type: ApplicationFiled: July 2, 2009Publication date: November 17, 2011Inventors: Marie Abitbol, Stéphane Blot
-
Publication number: 20110275526Abstract: A glycosyl transferase from Chinese hamster and related methods are described.Type: ApplicationFiled: November 10, 2010Publication date: November 10, 2011Applicant: MOMENTA PHARMACEUTICALS, INC.Inventor: James W. Meador, III
-
Publication number: 20110275085Abstract: The present invention relates to the field of diagnostics, especially to the detection of autoimmune diseases such as rheumatoid arthritis. Particularly, the invention provides a method for detecting the presence or absence of rheumatoid arthritis, or of a predisposition therefore or for monitoring rheumatoid arthritis in a subject using expression data of target genes related to immune system and tools of bioinformatics.Type: ApplicationFiled: December 1, 2009Publication date: November 10, 2011Applicant: TERVEYDEN JA HYVINVOINNIN LAITOSInventors: Harri Salo, Jarno Honkanen, Outi Vaarala
-
Publication number: 20110275083Abstract: The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.Type: ApplicationFiled: December 17, 2010Publication date: November 10, 2011Inventors: Michael C. Kiefer, Joffre B. Baker, James Hackett
-
Publication number: 20110277050Abstract: Embodiments of the present invention describe a novel and versatile inducible binary expression system (the ‘Q system’) and methods for controlling transgene expression in vitro and in vivo, for lineage tracing, for genetic mosaic analysis and for determining gene function.Type: ApplicationFiled: March 11, 2011Publication date: November 10, 2011Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Liqun Luo, Christopher Potter, Bosiljka Tasic
-
Publication number: 20110275082Abstract: The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.Type: ApplicationFiled: December 17, 2010Publication date: November 10, 2011Inventors: MICHAEL C. KIEFER, JOFFRE B. BAKER, JAMES HACKETT
-
Patent number: 8053189Abstract: The object of the present invention refers to an in vitro method for diagnosing colorectal cancer based on the determination from a biological sample obtained from a subject, of promoter methylation status of at least one of the genes APC, RARB2 and p14 and, optionally, MGMT and p16. Likewise, object of the present invention is a kit for performing the method of the invention.Type: GrantFiled: November 3, 2008Date of Patent: November 8, 2011Assignee: Fina Biotech, S.L.U.Inventors: Gabriel Capella Munar, Daniel Azuara García
-
Publication number: 20110269637Abstract: The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient.Type: ApplicationFiled: July 2, 2009Publication date: November 3, 2011Applicant: ASSISTANCE PUBLIQUE-HOPITAUX DE PARISInventors: Philippe Broët, Sophie Camilleri-Broët, Lance Miller, Patrick Tan
-
Publication number: 20110269145Abstract: The present invention relates to methods and compositions for identifying biomarkers that indicate a biological state, in particular cancer or predisposition to cancer.Type: ApplicationFiled: March 30, 2009Publication date: November 3, 2011Applicant: UNIVERSITY OF TOLEDOInventors: James C. Willey, Thomas M. Blomquist, Erin L. Crawford, D'Anna N. Mullins
-
Patent number: 8048634Abstract: A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation rate of the CpG sequence in at least one target gene of the test specimen, wherein the target genes is consisted of PTPRR, ZNF582, PDE8B and DBC1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the methylation rate in the target gene.Type: GrantFiled: August 18, 2009Date of Patent: November 1, 2011Assignee: National Defense Medical CenterInventor: Hung-Cheng Lai
-
Publication number: 20110262928Abstract: The present invention encompasses miRNA profiles and type-I IFN/IFN?-induced PD marker profiles in inflammatory or autoimmune disorders, such as myositis. The profiles may also be used in, for example, methods of treating patients, methods of monitoring disease progression of patients, and in diagnosing or providing a prognosis to patients having inflammatory or autoimmune disorders.Type: ApplicationFiled: February 6, 2009Publication date: October 27, 2011Applicant: Medimmune LLCInventors: Yihong Yao, Chris Moorehouse, Brandon Higgs, Bahija Jallal, Steven A. Greenberg
-
Publication number: 20110262920Abstract: A method for survival prediction in cancer patients is provided. In one embodiment, the survival prediction is determined by the presence or absence of KRAS gene region deletion and/or loss of Chromosome 12 (Ch. 12) in cancer tumor tissue. In another embodiment, the presence or absence of KRAS gene region deletion and/or loss of Ch. 12 in cancer tumor tissue is used to predict survival in non-small-cell lung cancer (NSCLC) patients.Type: ApplicationFiled: March 16, 2011Publication date: October 27, 2011Inventors: Yun Yen, Qiang Liu
-
Publication number: 20110262451Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of isovaleryl-coenzyme A dehydrogenase (IVD), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.Type: ApplicationFiled: May 7, 2009Publication date: October 27, 2011Inventors: Jérôme Aubert, Tony Minier, Valérie Trinquet, Michel Rivier
-
Publication number: 20110262930Abstract: Polypeptides which are related to the neprilysin enzyme family and have zinc metalloprotease activities and are referred to as IGS5, polynucleotides encoding such polypeptides, vectors containing such polynucleotides, host cells containing such vectors, processes for producing such polypeptides and/or polynucleotides, screening methods for identifying compounds which stimulate or inhibit IGS5 polypeptides and/or polynucleotides, and the use of such polypeptides and/or polynucleotides in therapy of various dysfunctions, disorders or diseases, particularly cardiovascular diseases, metabolic diseases such as diabetes mellitus type II, and neurodegenerative disorders, such as Parkinson's Disease.Type: ApplicationFiled: May 25, 2011Publication date: October 27, 2011Applicant: Abbott Healthcare Products B.V.Inventors: Willy DELEERSNIJDER, Yasmin Karimi-Nejad, Michael Weske, Dieter Ziegler
-
Publication number: 20110262929Abstract: The present invention provides antibodies that bind to HS6ST2 proteins, pharmaceutical compositions comprising the antibodies as active ingredients, methods for diagnosing cancer using the antibodies, HS6ST2 proteins conjugated to cytotoxic agents and pharmaceutical compositions comprising the HS6ST2 proteins as active ingredients.Type: ApplicationFiled: December 22, 2009Publication date: October 27, 2011Applicant: FORERUNNER PHARMA RESEARCH CO., LTD.Inventors: Shigeto Kawai, Naoki Kimura
-
Publication number: 20110257034Abstract: Closures for containers and methods for using same are provided. In a general embodiment/the present disclosure provides a closure having a top portion (12), a bottom portion (14) and a side portion (16), an aperture (18) extending though the closure, a projection (20) extending from the closure and at least two rib members (36) on an interior of the projection. The projection may also include a cover (22). In another embodiment, a method for using a closure includes inserting a. spike member into a projection, piercing a membrane that hermetically seals a medical container, pushing rib members within the projection to center the spike member inserted into the projection, and tearing the membrane to create a vent hole in the membrane.Type: ApplicationFiled: October 13, 2009Publication date: October 20, 2011Applicants: CORNELL UNIVERSITY, THE TRUSTEES OF PRINCETON UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Francis Barany, Owen Parker, Manny D. Bacolod, Sarah F. Giardina, Yu-wei Cheng, Daniel A. Notterman, Gunter S. Schemmann, Philip B. Paty, Monib Zirvi
-
Publication number: 20110257167Abstract: Provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by a LKB1 and/or AMPK gene or protein loss or mutation.Type: ApplicationFiled: February 3, 2011Publication date: October 20, 2011Inventors: Rajesh Chopra, Yuhong Ning, Sabita Sankar, Shuichan Xu, Weiming Xu
-
Publication number: 20110250604Abstract: Methods of detecting a source of a microbial contamination in a suspect sample include detecting at least one member selected from the group consisting of a microbial geosmin synthase, a microbial 2-methylisoborneol synthase and a microbial 2-methylgeranyl diphosphate synthase in the suspect sample. The method can include conducting a nucleic acid amplification assay in the presence of at least one member selected from the group consisting of at least one microbial geosmin primer and at least one microbial 2-methylisoborneol synthase primer on a sample obtained from a suspect source of the microbial contamination.Type: ApplicationFiled: March 15, 2011Publication date: October 13, 2011Inventors: David Cane, Steven Giglio, Jiaoyang Jiang, Christopher P. Saint, Paul T. Monis
-
Publication number: 20110250610Abstract: Methods for the fermentative production of isobutanol is provided by the fermentative growth of a recombinant microorganism expressing a highly active ketol-acid reductoisomerase enzyme in addition to other enzymes required for conversion of glucose to isobutanol.Type: ApplicationFiled: February 22, 2011Publication date: October 13, 2011Applicant: BUTAMAX(TM) ADVANCED BIOFUELS LLCInventors: DER-ING LIAO, MARK J. NELSON, MICHAEL G. BRAMUCCI
-
Publication number: 20110250611Abstract: Disclosed are mammalian expression vectors for expressing simultaneous expression of immunoglobulins as both a secreted and cell surface bound form.Type: ApplicationFiled: April 19, 2011Publication date: October 13, 2011Applicant: ABBOTT BIOTHERAPEUTICS CORP.Inventors: Robert DuBridge, Wenge Zhang, Susan Rhodes
-
Publication number: 20110251086Abstract: The current invention relates to new tools and methods enabling neuroblastoma patient stratification into prognostic favorable or unfavorable groups. The invention is based on the re-analysis of published gene expression data-sets studying neuroblastoma tumors generating different prognostic gene lists. The overlapping gene lists were subsequently tested for their prognostic power on both the published tumor samples and on an unseen large set of unpublished samples, greatly increasing the statistical power of prognostic analyses. In addition, expression analysis of miRNAs in neuroblastoma tumors with different prognosis was performed. By doing this, the inventors could establish a neuroblastoma prognostic classifier with highly improved prognostic power, which is independent from the tumor sample set used to establish it. This classifier and its related prognostic tools and methods are thus perfectly suitable for routine clinical assessment of neuroblastoma prognosis.Type: ApplicationFiled: December 10, 2009Publication date: October 13, 2011Inventors: Joke Vandesompele, Katleen Preter, Pieter Mestdagh, Franki Speleman, Joëlle Vermeulen
-
Publication number: 20110250609Abstract: This invention relates to non-radioactive markers that facilitate the detection and analysis of nascent proteins translated within cellular or cell-free translation systems. Nascent proteins containing these markers can be rapidly and efficiently detected, isolated and analyzed without the handling and disposal problems associated with radioactive reagents. Preferred markers are dipyrrometheneboron difluoride (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) dyes.Type: ApplicationFiled: February 9, 2011Publication date: October 13, 2011Inventors: Kenneth J. Rothschild, Sadanand Gite, Jerzy Olejnik
-
Publication number: 20110252509Abstract: This invention relates generally to a method for producing a transgenic cell with increased gamma-aminobutyric acid (GABA) content as compared to a corresponding non-transformed wild type cell.Type: ApplicationFiled: October 23, 2009Publication date: October 13, 2011Applicant: BASF Plant Sceince GmbHInventors: Janneke Hendriks, Hardy Schön, Oliver Thimm, Volker Haake, Gunnar Plesch, Piotr Puzio, Astrid Blau, Michael Manfred Herold, Birgit Wendel, Beate Kamlage, Florian Schauwecker